Genetic Engineering of HEK293 Cell Lines for Efficient Production of Difficult to Express Proteins

  • gene therapy applications
  • biotherapeutics


Production of viral-based gene therapies and some therapeutic proteins are difficult to achieve on industrial scale with high yield, quality and efficacy. This is due to the complexity and toxicity of viral or other proteins that inherently inhibit cell proliferation; thus, limiting their productivity. This invention seeks to use currently available molecular tools for genetic engineering to develop dedicated mammalian packaging/producer cell lines that can significantly improve production efficiency of specific biotherapeutics, especially in the case of viral, toxic, or difficult to manufacture entities.


The technology utilizes stably-modified, clonally-derived cell lines designed with a ‘proliferate-then-produce’ concept for manufacturing biopharmaceuticals to overcome the issues related to inhibition of cell division by concurrent synthesis of the intended product. It is based on stable genomic integration of one or two separate artificially introduced genetic constructs within the same cell: a. ER-Cre-ER (inducible recombinase) cassette; and/or b. mitogen excisable/GOI inducible cassette.

Contact Information

Name: Shyamala Rajagopalan


Phone: 979-862-3002